Tractus Crossing Support Catheter with its Jigsaw TechnologyTM Receives 510(k) Clearance

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Tractus Vascular, LLC today announced the 510(k) clearance of the TractusTM Crossing Support Catheter (CSC) with 0.014, 0.018 and 0.035 guidewire compatibility and lengths of 90, 135, 155 and 170 cm. The TractusTM CSC represents a highly novel approach to treating vascular disease. While most crossing support catheters are constructed with a braided sheath, Tractus offers their Jigsaw TechnologyTM laser cut stainless steel shaft consisting of a continuous helical cut pattern forming interlocking teeth. Distal gusset cuts offer a continuous stainless steel tip which extends the attributes of this novel catheter shaft.

The TractusTM CSC is intended to be used during interventional procedures in the peripheral and coronary vasculature to support a guidewire and facilitate access in discrete regions, allow for guidewire exchanges, and provide a conduit for delivering saline solutions and contrast media. Tractus Chairman and CEO/CTO, Janet Burpee, said This FDA clearance is the first of many milestones in bringing to market technology that capitalizes on the economies in todays catheter laboratories while always prioritizing patient outcomes and user needs.

Tractus Vascular, LLC was created from incubator company Tinker Med, LLC. Tinker Med was originally a wholly owned subsidiary of Burpee MedSystems, LLC. Janet Burpee added, With the sale of Burpee MedSystems, Tinker Med can now focus all efforts on its own companies which include Tractus Vascular and Venarum Medical.

Reference: https://www.businesswire.com/news/home/20190404005545/en/Seisa-Medical-Announces-Acquisition-Burpee-MedSystems

About Tractus Vascular, LLC

Chronic total occlusion (CTO) remains one of the most challenging pathologies encountered by surgeons and interventionists in performing endovascular interventions. CTO in the arterial vasculature is characterized by heavy arteriosclerotic plaque burden resulting in complete, or near complete occlusion of a vessel. The reported rate of CTO in patients who undergo treatment of symptomatic peripheral artery disease (PAD) is approximately 40% and is cited as one of the primary reasons for procedural failures. CTO in the venous vasculature, also known as chronic venous occlusion, is most common in the legs and is characterized by vein wall remodeling, collagenous fibrosis, and luminal reduction. Tractus is dedicated to creating catheter products that excel in the treatment of challenging lesions while moderating unit cost. Tractus intends to use its Jigsaw TechnologyTM to expand its product family of crossing devices.

Janet Burpee, CEO

Tractus Vascular, LLC

[email protected]

(732) 590-1470